Disease Domain | Count |
---|---|
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
T-lymphocyte cell therapy | 2 |
Top 5 Target | Count |
---|---|
KRAS G12D(GTPase KRas G12D) | 2 |
Target |
Mechanism KRAS G12D inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism KRAS G12D inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date20 Oct 2023 |
Sponsor / Collaborator |
Start Date05 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
KRASG12D-specific T cells (Myongji Hospital) ( KRAS G12D ) | KRAS mutant Colorectal Cancer More | Preclinical |
Non-engineered T cells(Myongji Hospital) ( KRAS G12D ) | Colorectal Cancer More | Preclinical |